Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges

•Ruxolitinib is associated with high rates of response in patients who failed prior lines.•Adverse events are consistent with prior studies and include infections and hematologic toxicity.•Ruxolitinib is an effective steroid-sparing agent; steroid reduction occurred in 75% of patients.•Gradual tapering of ruxolitinib seems feasible in selected cases without graft-versus-host disease flares.